Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Settles Dispute over Lab Sale

Premium

Rosetta Genomics said this week that it has settled a dispute with Sanra Laboratories in connection with Rosetta’s sale of Parkway Laboratories to Sanra in 2009.

As reported by Gene Silencing News, Rosetta bought Parkway for $2.9 million in 2008 in order to pick up the expertise and infrastructure needed to begin marketing its line of microRNA-based diagnostics (GSN 6/12/2008).

Rosetta used Parkway’s CLIA certification to establish its own CLIA-certified lab where it performs its miRNA tests, and sold off Parkway to Sanra the next year for up to $2.5 million, payable over six years as a fixed percentage of revenues (GSN 5/21/2009).

This week, Rosetta said that Sanra has agreed to use its “best efforts” to pay Rosetta $625,000, in addition to all sums previously paid, to meet obligations under a stock-purchase deal inked in conjunction with the Parkway sale.

Additional terms of the settlement were not disclosed.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.